Skip to main content
. Author manuscript; available in PMC: 2013 Jun 27.
Published in final edited form as: Leuk Lymphoma. 2009 Mar;50(3):349–356. doi: 10.1080/10428190902730227

Figure 1.

Figure 1

Decline in CD3-positive T-cell subsets after 1 cycle of clofarabine. Four colour flow cytometry with directly conjugated antibodies for CD3 performed prior to clofarabine therapy, on day 5 of cycle 1, and immediately prior to the start of cycle 2 demonstrate an 84.7% (range 69.7–96.5%) median decline in absolute CD3+ T-cells. Samples were available at all three time points (pre-treatment, day 5 of cycle 1, and prior to cycle 2) in patients 1, 3–6 and from two time points (pre-treatment and day 5) in patient 2.